Abiopharma

Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial

IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QIAGEN announces adjustment of conversion price under its US$750,000,000 Convertible Bonds due 2032

QIAGEN announces adjustment of conversion price under its US$ 500,000,000 Convertible Bonds due 2027

QIAGEN announces adjustment of conversion price under its US$ 500,000,000 Convertible Bonds due 2031

Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Fortrea Announces Updated Presentation Time at Upcoming J.P. Morgan Healthcare Conference

How the SWE ECP AG Helped With My Communication Anxiety